Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Receivables - Net: 2024-2025

  • Stoke Therapeutics' Receivables - Net was N/A to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Stoke Therapeutics reported Receivables - Net of $9.2 million as of Q3 2025, which was up 454.44% from $1.7 million recorded in Q4 2024.
  • Stoke Therapeutics' Receivables - Net's 5-year high stood at $9.2 million during Q3 2025, with a 5-year trough of $1.7 million in Q4 2024.
  • Over the past 2 years, Stoke Therapeutics' median Receivables - Net value was $5.5 million (recorded in 2024), while the average stood at $5.5 million.